MB8 Stock Overview
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moberg Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.88 |
| 52 Week High | kr3.23 |
| 52 Week Low | kr0.49 |
| Beta | 1.08 |
| 1 Month Change | 27.52% |
| 3 Month Change | 104.40% |
| 1 Year Change | 44.24% |
| 3 Year Change | -47.50% |
| 5 Year Change | -95.40% |
| Change since IPO | -91.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| MB8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 19.3% | 2.3% | 0.5% |
| 1Y | 44.2% | -28.6% | 1.3% |
Return vs Industry: MB8 exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: MB8 exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| MB8 volatility | |
|---|---|
| MB8 Average Weekly Movement | 19.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MB8's share price has been volatile over the past 3 months.
Volatility Over Time: MB8's weekly volatility has decreased from 27% to 19% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 10 | Anna Ljung | www.mobergpharma.se |
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. The company develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
Moberg Pharma AB (publ) Fundamentals Summary
| MB8 fundamental statistics | |
|---|---|
| Market cap | €81.74m |
| Earnings (TTM) | -€1.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-45.3x
P/E RatioIs MB8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MB8 income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr21.09m |
| Earnings | -kr21.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MB8 perform over the long term?
See historical performance and comparison